Jefferies Group’s Royalty Pharma RPRX Stock Holding History

Jefferies Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$864K	Buy	21,500 +16,999	+378%	+$726K	0.01%	848
2022 Q2	$189K	Buy	+4,501	New	+$185K	﹤0.01%	1286
2022 Q1	–	Sell	-620	Closed	-$24.7K	–	1895
2021 Q4	$24.7K	Buy	+620	New	+$24.1K	﹤0.01%	1547
2020 Q4	–	Sell	-59,100	Closed	-$2.49M	–	1766
2020 Q3	$2.49M	Buy	+59,100	New	+$2.54M	0.03%	492

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Jefferies Group's RPRX Position: Q3 2022 in Review

Jefferies Group increased its Royalty Pharma (RPRX) stake by 378% in Q3 2022, buying an estimated $726K and bringing the position to 21,500 shares worth $864K. The position accounts for 0.01% of the portfolio, ranked #848.

Jefferies Group first reported a position in RPRX in Q3 2020 and has held it in 4 quarters since. The position peaked at $2.49M in Q3 2020. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

Jefferies Group held 21,500 shares of Royalty Pharma worth $864K as of Q3 2022.
Jefferies Group bought 16,999 Royalty Pharma shares in Q3 2022, an estimated $726K.
Royalty Pharma made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #848 holding.
Jefferies Group first reported a position in Royalty Pharma in Q3 2020 and has held it in 4 quarters since.
Jefferies Group's Royalty Pharma position peaked at $2.49M in Q3 2020.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.